Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
October 21, 2021 09:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
October 15, 2021 09:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a...
Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
August 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating...